InflaRx Regains Nasdaq Compliance, Removing Delisting Threat
IFRX has more than doubled off its 52-week low of $0.711.
Summary
InflaRx N.V. announced it has regained compliance with Nasdaq's minimum bid price requirement, as its ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive business days. This formal notification from Nasdaq confirms the resolution of a significant compliance issue. While the stock price action leading to compliance already occurred, this announcement removes the immediate threat of delisting, which is a material positive for investor confidence, especially for a small-cap biopharmaceutical company. This event follows a recent 6-K filing where shareholders approved an increase in authorized share capital, which could have been a preparatory measure for a reverse stock split if the price had not recovered naturally. Investors will now watch for continued price stability and progress on the company's drug pipeline.
At the time of this announcement, IFRX was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.4M. The 52-week trading range was $0.71 to $1.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.